Belén Garijo, the chief executive officer of Healthcare at Merck KGaA and executive board member at the family-controlled group since January 2015 – has just visited staff in the UK to assure them that the British referendum decision June 23 to exit the European Union will not lead to a decline in the company's R&D investment or innovative efforts there. Rather, the German group will boost its activities in the country.
"We are very committed to keep developing our activities in the UK, because Britain is a highly attractive location for research and innovation and therefore we are in fact going to step up our development activities in the UK because the UK is a complex market access country and we need to be well represented here
